https://scholars.lib.ntu.edu.tw/handle/123456789/558194
標題: | Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities | 作者: | CHIA-YU CHU KUAN-YU CHEN Wen-Cheng Chang J. Wei Y.-F. Lee C.-H. Wang W.-M. |
公開日期: | 2017 | 出版社: | Elsevier B.V. | 卷: | 116 | 期: | 6 | 起(迄)頁: | 413-423 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Background/Purpose This report describes the 2016 consensus of the Taiwanese Dermatological Association (TDA) regarding the definition, classification, diagnosis, prevention, and management of skin toxicities resulting from treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This consensus is distributed to practices throughout Taiwan to provide recommendations for the diagnosis and treatment of such skin toxicities in order to improve the quality of life of patients undergoing EGFR-TKI treatment. The consensus thus serves as an important reference for dermatologists and other interested clinicians, such as oncologists, throughout Taiwan. Methods All the consensus contents were voted on by the participating experts, with approval by no less than 75% required for inclusion. Results The consensus provides a comprehensive overview of EGFR-TKI skin toxicities, including recent advances in identifying their causes and the processes by which they develop. Conclusion All the consensus meeting attendees agreed that there are several major EGFR-TKI-related skin toxicities, including acneiform rash (i.e., papulopustular rash), xeroderma, pruritus, paronychia, stomatitis, mucositis, and hair changes (such as hair loss, slowed hair growth, and trichomegaly). The experts were also generally unanimous in their voting on the specific definitions, onset times, and care suggestions for each of those skin toxicities. Furthermore, the recommended treatment algorithms for the various skin toxicities were ultimately approved by 100% (15/15) of the consensus attendees. ? 2017 |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85016043505&doi=10.1016%2fj.jfma.2017.03.001&partnerID=40&md5=2fe93d9c71ab40e273d4f5f6c7839c97 https://scholars.lib.ntu.edu.tw/handle/123456789/558194 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2017.03.001 | SDG/關鍵字: | afatinib; antibiotic agent; antihistaminic agent; antiinflammatory agent; aprepitant; cefalexin; chlorpheniramine maleate; corticosteroid; doxepin; doxycycline; epidermal growth factor receptor kinase inhibitor; erlotinib; fusidic acid; gabapentin; immunosuppressive agent; local anesthetic agent; minocycline; minoxidil; petrolatum; pramocaine; pregabalin; salicylic acid; steroid; tetracycline; urea; epidermal growth factor receptor; protein kinase inhibitor; acne; antibiotic therapy; Article; cancer patient; consensus development; corticosteroid therapy; cream; dermatologist; disease severity; drug eruption; drug safety; drug tolerability; hair; hair loss; health care organization; human; humidifier; immunosuppressive treatment; incidence; medical expert; mucosa inflammation; non small cell lung cancer; nurse; oncologist; paronychia; patient care; physician; protective clothing; pruritus; pulmonologist; skin care; skin toxicity; steroid therapy; stomatitis; surgeon; Taiwan; xeroderma; antagonists and inhibitors; consensus development; drug eruption; medical society; Drug Eruptions; Humans; Protein Kinase Inhibitors; Receptor, Epidermal Growth Factor; Societies, Medical; Taiwan |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。